Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 10,147

Document Document Title
WO/2009/153457A3
The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effect...  
WO/2009/149807A1
The present invention relates to compounds of the formulae (I), (II) and (III), to the use of compounds containing at least one perfluoro-tert-butoxy group and at least one substituted or unsubstituted aromatic end group as surface-activ...  
WO/2009/148052A1
Disclosed is a sulfonamide compound represented by general formula (1) that can be used as an effective component in a CaSR antagonist that is extremely effective in preventing and/or treating bone diseases, such as osteoporosis. Said co...  
WO/2009/146871A1
The use of compounds of the formula (I) Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 (I) where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are select...  
WO/2009/147632A3
The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza- undecane-2,4,8,10-tetraol.  
WO/2009/148600A8
This invention relates to novel lysine-based compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use o...  
WO/2009/148600A2
This invention relates to novel lysine-based compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use o...  
WO/2009/147632A2
The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza- undecane-2,4,8,10-tetraol.  
WO/2009/148600A3
This invention relates to novel lysine-based compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use o...  
WO/2009/145219A1
Disclosed is a means for treating Alzheimer's disease, which utilizes a secretase inhibitor and is highly safe. Specifically disclosed is a compound represented by general formula (I) [wherein A represents a phenyl group or the like; R1...  
WO/2009/145989A3
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2009/145989A2
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2009/144344A2
Compound for labelling biomolecules based on vinylsulphone, preparation and uses, comprising a labelling molecule and a vinylsulphone group. In addition it relates to the use of the compounds as labelling agents, to the procedure of obta...  
WO/2009/144344A3
Compound for labelling biomolecules based on vinylsulphone, preparation and uses, comprising a labelling molecule and a vinylsulphone group. In addition it relates to the use of the compounds as labelling agents, to the procedure of obta...  
WO/2009/140743A3
The invention generally relates to the application of imaging techniques, in particular positron emission tomography (PET) or single photon emission tomography (SPECT), in the assessment of physiological parameters in a subject. The comp...  
WO/2009/142984A1
Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the c...  
WO/2009/138758A2
There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of disease...  
WO/2009/138758A3
There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of disease...  
WO/2009/136608A1
Disclosed is an ionic liquid having a low viscosity, a low melting point, high electrical conductivity and high thermal stability. The ionic liquid is composed of fluorosulfonyl(trifluoromethylsulfonylamide) (FTA) anions and cations of ...  
WO/2009/136617A1
Disclosed is a process for producing a compound having an antagonistic activity on a NPYY5 receptor. Also disclosed is a useful crystal. A compound represented by formula (II) [wherein R1 represents a substituted or unsubstituted alkyl;...  
WO/2009/132241A3
Materials are provided that may be useful as ionomers or polymer ionomers, including compounds including bis sulfonyl imide groups which may be highly fluorinated and may be polymers.  
WO/2009/131065A1
Disclosed is a compound useful as a prophylactic agent or a therapeutic agent for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases, gastrointestinal diseases, neoplasm, infectious diseases and others...  
WO/2009/128088A2
The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carved...  
WO/2009/129246A2
This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.  
WO/2009/127723A1
The invention relates to substituted arylsulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical compositi...  
WO/2009/128088A3
The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carved...  
WO/2009/127822A3
There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases ...  
WO/2009/129246A3
This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.  
WO/2009/127822A2
There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases ...  
WO/2009/124962A3
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.  
WO/2009/125606A1
Provided is a compound represented by formula (I) having a PAI-1 inhibiting action. [In formula (I), R1 represents an optionally substituted C6-10 aryl group etc., T represents a single bond etc., m is 0 or 1, when m is 0 G represents -N...  
WO/2009/124962A2
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.  
WO/2009/124022A1
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...  
WO/2009/119858A1
Disclosed is a novel benzene compound which has an excellent immunosuppressing activity, an excellent rejection-inhibiting effect and others, and is reduced in adverse side effects including bradycardia. Specifically disclosed is a compo...  
WO/2009/118168A1
The invention relates to compounds which have an affinity to the ยต-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...  
WO/2009/118292A1
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by a...  
WO/2009/115257A1
The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicament containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.  
WO/2009/113704A3
The present invention provides an amphiphilic fluorine-containing compound having a structure represented by the following general formula (1) including a hydrophilic ligand Rl, a fluorine probe Rf, and linkers L1 and L2. In the formula,...  
WO/2009/111277A9
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatme...  
WO/2009/111277A1
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatme...  
WO/2009/111278A3
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnos...  
WO/2009/111280A1
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treat...  
WO/2009/111279A1
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, ...  
WO/2009/106361A2
The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.  
WO/2009/106361A3
The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.  
WO/2009/103778A1
A compound of formula (1) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from pain, fever, inflammation and ca...  
WO/2009/105751A1
The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target ...  
WO/2009/101201A3
The object of the present invention is mixtures of ionic and/or like hydrides and ionic liquids and use of such mixtures.  
WO/2009/101201A2
The object of the present invention is mixtures of ionic and/or like hydrides and ionic liquids and use of such mixtures.  
WO/2009/100095A1
Compounds according to the formula below are disclosed herein: Therapeutic methods for the treatment of pain, compositions, and medicaments related thereto are also disclosed.  

Matches 401 - 450 out of 10,147